RYTM · Insider Trading
Rhythm Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by RYTM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-14 | David P Meeker | President and CEO | MIXED | — | −$4.83M |
| 2026-09-01 | Hunter C Smith | Chief Financial Officer | MIXED | −5,587 | −$5.15M |
| 2026-08-18 | Manher Joshi | Chief Medical Officer | A | +75,000 deriv. | — |
| 2026-08-17 | Alastair Garfield | Chief Scientific Officer | Sell | −7,763 | −$912.70K |
| 2026-08-17 | Joseph Shulman | Chief Technical Officer | MIXED | −3,055 | −$594.45K |
| 2026-08-14 | Jennifer Kayden Lee | EVP, Head of North America | MIXED | −19,233 | −$7.90M |
| 2026-08-14 | Yann Mazabraud | EVP, Head of International | MIXED | −10,375 | −$6.30M |
| 2026-07-02 | Alastair Garfield | Chief Scientific Officer | MIXED | +2,295 | −$237.38K |
| 2026-06-25 | Jennifer L Good | Director | M | +4,712 | — |
| 2026-06-25 | David W J McGirr | Director | M | +4,712 | — |
| 2026-06-25 | Lynn A. Tetrault | Director | M | +4,712 | — |
| 2026-06-25 | Christophe Jean | Director | M | +4,712 | — |
| 2026-06-25 | Stuart A Arbuckle | Director | M | +4,712 | — |
| 2026-06-24 | Lynn A. Tetrault | Director | MIXED | — | −$2.67M |
| 2026-05-20 | Hunter C Smith | Chief Financial Officer | M | +3,000 | +$53.61K |
| 2026-05-19 | Christopher Paul German | Corporate Controller & CAO | MIXED | −201 | −$240.82K |
| 2026-04-03 | Yann Mazabraud | EVP, Head of International | M | +12,875 | — |
| 2026-04-03 | Kimberly J Popovits | Director | A | +17,065 deriv. | — |
| 2026-03-16 | Edward T Mathers | Director | J | +4,199 | — |
| 2026-03-06 | Christopher Paul German | Corporate Controller & CAO | MIXED | −4,114 | −$475.83K |
| 2026-03-04 | Edward T Mathers | Director | J | +4,198 | — |
| 2026-03-04 | Yann Mazabraud | EVP, Head of International | A | +35,000 deriv. | — |
| 2026-03-03 | Christopher Paul German | Corporate Controller & CAO | MIXED | +820 | −$32.47K |
| 2026-03-02 | Hunter C Smith | Chief Financial Officer | M | +6,099 | +$41.47K |
| 2026-02-19 | Hunter C Smith | Chief Financial Officer | Sell | −7,954 | −$805.81K |
| 2026-02-18 | Yann Mazabraud | EVP, Head of International | M | +10,000 | — |
| 2026-02-13 | Yann Mazabraud | EVP, Head of International | A | +23,350 deriv. | — |
| 2026-02-13 | Christopher Paul German | Corporate Controller & CAO | A | +5,215 deriv. | — |
| 2026-02-13 | Jennifer Kayden Lee | EVP, Head of North America | A | +54,150 deriv. | — |
| 2026-02-13 | Alastair Garfield | Chief Scientific Officer | A | +41,650 deriv. | — |
| 2026-02-13 | David P Meeker | President and CEO | A | +179,750 deriv. | — |
| 2026-02-13 | Pamela J. Cramer | Chief Human Resources Officer | A | +29,150 deriv. | — |
| 2026-02-13 | Joseph Shulman | Chief Technical Officer | A | +37,500 deriv. | — |
| 2026-02-12 | Hunter C Smith | Chief Financial Officer | Sell | −7,071 | −$708.58K |
| 2026-02-06 | Hunter C Smith | Chief Financial Officer | Sell | −6,628 | −$702.74K |
| 2026-02-03 | Joseph Shulman | Chief Technical Officer | MIXED | +10,461 | −$709.20K |
| 2026-02-03 | Christopher Paul German | Corporate Controller & CAO | MIXED | +2,475 | −$124.03K |
| 2026-02-03 | Hunter C Smith | Chief Financial Officer | MIXED | +15,250 | −$1.17M |
| 2026-02-03 | Alastair Garfield | Chief Scientific Officer | MIXED | +4,637 | −$220.81K |
| 2026-02-03 | Jennifer Kayden Lee | EVP, Head of North America | MIXED | +13,375 | −$1.01M |
| 2026-02-03 | Pamela J. Cramer | Chief Human Resources Officer | MIXED | +8,562 | −$515.63K |
| 2026-02-03 | David P Meeker | President and CEO | MIXED | +37,191 | −$3.44M |
| 2026-02-03 | Yann Mazabraud | EVP, Head of International | M | +5,500 | — |
| 2025-12-15 | Pamela J. Cramer | Chief Human Resources Officer | MIXED | — | −$280.23K |
| 2025-11-24 | Pamela J. Cramer | Chief Human Resources Officer | MIXED | — | −$260.13K |
| 2025-11-12 | Pamela J. Cramer | Chief Human Resources Officer | MIXED | — | −$2.00M |
| 2025-11-03 | Joseph Shulman | Chief Technical Officer | MIXED | — | −$824.52K |
| 2025-10-30 | Joseph Shulman | Chief Technical Officer | MIXED | — | −$244.37K |
| 2025-10-20 | Joseph Shulman | Chief Technical Officer | MIXED | — | −$1.18M |
| 2025-09-04 | Joseph Shulman | Chief Technical Officer | MIXED | — | −$1.26M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| David P Meeker | President and CEO | 252,073 | $28.72M |
| Hunter C Smith | Chief Financial Officer | 114,024 | $12.99M |
| Yann Mazabraud | EVP, Head of International | 55,655 | $6.34M |
| Jennifer Kayden Lee | EVP, Head of North America | 54,233 | $6.18M |
| Pamela J. Cramer | Chief Human Resources Officer | 34,107 | $3.89M |
| Edward T Mathers | Director | 21,168 | $2.41M |
| Joseph Shulman | Chief Technical Officer | 15,915 | $1.81M |
| David W J McGirr | Director | 11,712 | $1.33M |
| Jennifer L Good | Director | 11,712 | $1.33M |
| Christophe Jean | Director | 11,712 | $1.33M |
| Stuart A Arbuckle | Director | 11,712 | $1.33M |
| Lynn A. Tetrault | Director | 11,712 | $1.33M |
| Camille L Bedrosian | Director | 7,000 | $797.65K |
| Alastair Garfield | Chief Scientific Officer | 3,095 | $352.68K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RYTM quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.